The global advanced therapy medicinal products market is likely to grow at a CAGR of 13.4% over the forecast period, i.e., 2022-2031. The market generated a revenue of around USD 9,000 Million at the end of 2021 and is likely to produce revenue worth of nearly USD 32,000 Million by the end of 2031. Rising prevalence of genetic disorder along with the greater adoption of gene therapy, followed by the rise in prevalence of neurological disorders and growing research and development in the field of developing advanced therapy medicinal products are some of the major factors anticipated to drive the growth of the market in the coming years.
The global advanced therapy medicinal products market is segmented by product, disease and by end user. On the basis of disease, the market is further fragmented into oncology, genetic disorder, CNS, dermatology, and others. The dermatology segment is anticipated to garner the highest revenue of close to USD 9,000 million by the end of 2031. Moreover, in 2021, the segment garnered a revenue of over USD 3,000 million. This growth is on the account of increasing cases of skin cancer and other problems. The dermatology segment is to grow at a CAGR of around 12% over the forecast period.
On the basis of region, the global advanced therapy medicinal products market is analyzed by the markets of North America, Europe, Latin America, Asia-Pacific and Middle-east and Africa. The market in the North America collected the highest revenue of near to USD 4,000 million in 2021. By the end of 2031, it is estimated to garner a revenue of USD 14,000 million, by growing at the CAGR of around 13% over the forecast period. Factors such as increased investment by private companies and increased cases of cancer is expected to boost the market growth in the region.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global advanced therapy medicinal products market that are included in the report are Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene,Inc., and others.
The global advanced therapy medicinal products market is segmented by product, disease and by end user. On the basis of disease, the market is further fragmented into oncology, genetic disorder, CNS, dermatology, and others. The dermatology segment is anticipated to garner the highest revenue of close to USD 9,000 million by the end of 2031. Moreover, in 2021, the segment garnered a revenue of over USD 3,000 million. This growth is on the account of increasing cases of skin cancer and other problems. The dermatology segment is to grow at a CAGR of around 12% over the forecast period.
On the basis of region, the global advanced therapy medicinal products market is analyzed by the markets of North America, Europe, Latin America, Asia-Pacific and Middle-east and Africa. The market in the North America collected the highest revenue of near to USD 4,000 million in 2021. By the end of 2031, it is estimated to garner a revenue of USD 14,000 million, by growing at the CAGR of around 13% over the forecast period. Factors such as increased investment by private companies and increased cases of cancer is expected to boost the market growth in the region.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global advanced therapy medicinal products market that are included in the report are Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene,Inc., and others.
Table of Contents
1. Introduction1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. Assumptions and Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
3.2.1. Manufacturers
3.2.2. Distributors
3.2.3. End Users
3.3. Secondary Research
3.4. Market Size Estimation
4. Executive Summary - Global Advanced Therapy Medicinal Products Market
5. Analysis of Market Dynamics
5.1. Drivers
5.2. Trends
6. Key Market Opportunities for Business Growth
7. Major Roadblocks for the Market Growth
8. Regulatory & Standard Landscape
9. Value Chain Analysis
10. Potential ATMP Treatment Analysis
11. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
12. Use Case Analysis
13. Pipeline Analysis
14. Analysis on the Manufacturing Process
15. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
16. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
17. Competitive Positioning
18. Competitive Landscape
18.1. Market Share Analysis of Major Players (%), 2021
18.2. Competitive Benchmarking
18.2.1. Novartis AG.
18.2.2. Takeda Pharmaceutical Company Limited
18.2.3. Gilead Sciences, Inc.
18.2.4. Bluebird Bio, Inc
18.2.5. BioMarin Pharmaceutical Inc
18.2.6. Vericel Corporation
18.2.7. Mallinckrodt Pharmaceuticals
18.2.8. UniQure N.V.
18.2.9. JCR Pharmaceuticals Co., Ltd.
18.2.10. Spark Therapeutics, Inc. (Parent Company: Roche)
18.2.11. Kolon TissueGene, Inc.
19. Global Advanced Therapy Medicinal Products Market Outlook
19.1. By Value (USD million)
19.2. By Product
19.2.1. CAR-T Therapy, 2021-2031F (USD million)
19.2.2. Gene Therapy, 2021-2031F (USD million)
19.2.3. Cell Therapy, 2021-2031F (USD million)
19.2.4. Tissue Engineered Product, 2021-2031F (USD million)
19.3. By Disease
19.3.1. Oncology, 2021-2031F (USD million)
19.3.2. Genetic Disorders, 2021-2031F (USD million)
19.3.3. CNS, 2021-2031F (USD million)
19.3.4. Dermatology, 2021-2031F (USD million)
19.3.5. Others, 2021-2031F (USD million)
19.4. By End-User
19.4.1. Hospitals & Clinics, 2021-2031F (USD million)
19.4.2. Research & Academic Institutes, 2021-2031F (USD million)
19.5. Global Advanced Therapy Medicinal Products Market by Region
19.5.1. North America, 2021-2031F (USD million)
19.5.2. Europe, 2021-2031F (USD million)
19.5.3. Asia-Pacific, 2021-2031F (USD million)
19.5.4. Latin America, 2021-2031F (USD million)
19.5.5. Middle East & Africa, 2021-2031F (USD million)
20. North America Advanced Therapy Medicinal Products Market Outlook
20.1. By Value (USD million)
20.2. By Product
20.2.1. CAR-T Therapy, 2021-2031F (USD million
20.2.2. Gene Therapy, 2021-2031F (USD million)
20.2.3. Cell Therapy, 2021-2031F (USD million)
20.2.4. Tissue Engineered Product, 2021-2031F (USD million)
20.3. By Disease
20.3.1. Oncology, 2021-2031F (USD million)
20.3.2. Genetic Disorders, 2021-2031F (USD million)
20.3.3. CNS, 2021-2031F (USD million)
20.3.4. Dermatology, 2021-2031F (USD million)
20.3.5. Others, 2021-2031F (USD million)
20.4. By End-User
20.4.1. Hospitals & Clinics, 2021-2031F (USD million)
20.4.2. Research & Academic Institutes, 2021-2031F (USD million)
20.5. By Country
20.5.1. US, 2021-2031F (USD million)
20.5.2. Canada, 2021-2031F (USD million)
21. Europe Advanced Therapy Medicinal Products Market Outlook
21.1. By Product
21.2. By Disease
21.3. By End User
21.4. By Country
21.4.1. UK, 2021-2031F (USD Million)
21.4.2. Germany, 2021-2031F (USD Million)
21.4.3. France, 2021-2031F (USD Million)
21.4.4. Italy, 2021-2031F (USD Million)
21.4.5. Spain, 2021-2031F (USD Million)
21.4.6. Russia, 2021-2031F (USD Million)
21.4.7. Netherlands, 2021-2031F (USD Million)
21.4.8. Rest of Europe, 2021-2031F (USD Million)
22. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
22.1. By Product
22.2. By Disease
22.3. By End User
22.4. By Country
22.4.1. China, 2021-2031F (USD Million)
22.4.2. India, 2021-2031F (USD Million)
22.4.3. Japan, 2021-2031F (USD Million)
22.4.4. South Korea, 2021-2031F (USD Million)
22.4.5. Singapore, 2021-2031F (USD Million)
22.4.6. Australia, 2021-2031F (USD Million)
22.4.7. Rest of Asia-Pacific, 2021-2031F (USD Million)
23. Latin America Advanced Therapy Medicinal Products Market Outlook
23.1. By Product
23.2. By Disease
23.3. By End User
23.4. By Country
23.4.1. Brazil, 2021-2031F (USD Million)
23.4.2. Argentina, 2021-2031F (USD Million)
23.4.3. Mexico, 2021-2031F (USD Million)
23.4.4. Rest of Latin America, 2021-2031F (USD Million)
24. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
24.1. By Product
24.2. By Disease
24.3. By End User
24.4. By Country
24.4.1. GCC, 2021-2031F (USD Million)
24.4.2. Israel, 2021-2031F (USD Million)
24.4.3. South Africa, 2021-2031F (USD Million)
24.4.4. Rest of Middle East & Africa, 2021-2031F (USD Million)
Companies Mentioned
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Bluebird Bio Inc.
- BioMarin Pharmaceuticals Inc.
- Vericel Corporation
- Mallinckrodt Pharmaceuticals
- UniQure N.V.
- JCR Pharmaceuticals Co. Ltd.
- Spark Therapeutics Inc.
- Kolon TissueGene,Inc.
